RE:Q2 CC snapshotMrMugsy wrote: Business Development - nothing dramatic noticed in the industry
- opportunities exist for Big Pharma
- our opportunities remain healthy but nothing new or dramatic
Exelon - loading into the channel from GUD's perspective - should see the effect of that in Q3
Drug shortages in Brazil - small delays (us/competition) but nothing major for us
Political landscape in LATAM - continue to monitor changes in how pharmas are paid on a macro level
- innovative assets and bundling for payers (stategy)
ERP System - live in 8 countries and 20 entities ... will be live in all countries by year end
Commercializing in Brazil in Q3 - Mexico and Chile in Q4
Lots of cash and cashflow for growth
Endo Bankruptcy - opportunity to buy Paladin ?
- Chapter 11 in USA takes a long time
- don't know if they will register for bankruptcy in Canada
- process could take a long time
Drop in Gilead portfolio starting in Q3 - minimal sales going forward with them
Markets back to normal in most countries - will see continued growth including Canada.
- spend will rise - more selling activities starting in Q3
- building a focused Exelon sales force
-----------------
Forgive any errors - went through CC quickly
Good summary - thanks Mugsy!
Any thoughts on zero buybacks in July and August (so far)?
The market seemed to like Q2... nobody knows how these will work out, but there's a fair chance we'll have some disappointment in Q3 or Q4 due to reasons you mentioned: mainly the Gileard portfolio and Exelon channel sales. Or perhaps not! Who knows. :)
On the other hand, we get to take over Exelon marketing, we have growing products, we have our salesforce out there, Akynzeo bringing in some money...
Also good to note that since they're terminating the Gilead deal, it probably added very little to the bottom line? So even though revenue takes a hit, profits will likely not.
Samira stayed on the Paladin question for a while (could have only said that they're always opportunistic). They're definitely paying attention to how that unfolds. It was interesting to hear that they prioritize Mexico and Canada when looking at deals (which are "suboptimal" right now).